Sarcoma  >>  retaspimycin (IPI-504)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
retaspimycin (IPI-504) / Infinity Pharma
NCT00276302: Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS)

Completed
1
63
US, Canada
IPI-504
Infinity Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
11/10
11/10

Download Options